CD117

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 2, 2024
Employment, Conference, Option, CSU, News, Therapy, Event, CD117

REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.

Key Points: 
  • REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will present at the 23rd Annual Needham Virtual Healthcare Conference at 11am EDT on April 8, 2024.
  • A live webcast of the presentation will be available on the Events & News – Presentations page of Jasper's Investor Relations website.
  • An archived replay of the presentation will be available on Jasper's website for 30 days following the live broadcast.
  • Each Option was granted pursuant to the Jasper Therapeutics, Inc.

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Retrieved on: 
Thursday, March 21, 2024
CD117, News, Conference, Therapy, Event, CSU

REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference at 10am EST on March 28, 2024.

Key Points: 
  • REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that its management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference at 10am EST on March 28, 2024.
  • A live webcast of the fireside chat will be available on the Events & News – Presentations page of Jasper's Investor Relations website.
  • An archived replay of the fireside chat will be available on Jasper's website for 30 days following the live broadcast.

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

Retrieved on: 
Tuesday, March 19, 2024
Patient, Cold urticaria, CSU, Trial of the century, B cell, Therapy, Safety, Pharmacokinetics, CD117, Pharmaceutical industry

REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU.

Key Points: 
  • REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), today announced that the first patient has been dosed in Jasper’s Phase 1b/2a (SPOTLIGHT) clinical study of subcutaneous briquilimab for the treatment of CIndU.
  • The SPOTLIGHT study is evaluating a single administration, at two different dose levels, of subcutaneous briquilimab in adult patients with cold urticaria (ColdU) or symptomatic dermographism (SD).
  • “We are excited to announce dosing of the first patient in the SPOTLIGHT study in patients with CIndU, our second clinical program evaluating briquilimab in a mast cell-mediated disease,” said Edwin Tucker, Chief Medical Officer of Jasper.
  • Jasper anticipates reporting preliminary data from the SPOTLIGHT study in the second half of 2024.

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

Retrieved on: 
Friday, March 15, 2024
Patient, Bone marrow failure, CSU, Clinical trial, Therapy, Definitive, CD117, FA

The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California.

Key Points: 
  • The data was presented at the 2024 Stanford Medicine Center for Definitive and Curative Medicine Symposium on March 13, 2024, in Palo Alto, California.
  • The ongoing investigator initiated Phase 1b/2a clinical trial is evaluating a conditioning regimen that includes intravenous briquilimab as a potential treatment for FA patients in bone marrow failure.
  • Data from the study show that briquilimab infusion has a promising safety profile and appears to be well tolerated in patients with FA, with all six patients treated achieving full donor engraftment and full blood count recovery.
  • “We’d like thank our collaborators at Stanford Medicine for their work evaluating briquilimab in this vulnerable patient population.”

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, March 4, 2024
AAAAI, Research, Syndrome, Omalizumab, Anaphylaxis, Option, Risk, Allergy, Annual general meeting, Therapy, Patient, Employment, CD117, CSU, Pharmaceutical industry

“2023 was a highly productive year for Jasper, as we shifted our operational focus toward briquilimab development in mast cell driven diseases,” said Ronald Martell, President and Chief Executive Officer.

Key Points: 
  • “2023 was a highly productive year for Jasper, as we shifted our operational focus toward briquilimab development in mast cell driven diseases,” said Ronald Martell, President and Chief Executive Officer.
  • Obtained regulatory clearance in the US and EU for initiation of its Phase 1b/2a BEACON study of subcutaneous briquilimab in CSU.
  • Jasper expects to report initial data from at least the first four cohorts of the study in the third quarter of 2024.
  • Jasper expects to conduct the study across four clinical sites in the EU and has activated three sites to date.

Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference

Retrieved on: 
Monday, February 26, 2024
Syndrome, Risk, Conference, Event, Therapy, News, CD117, CSU

REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the 43rd Annual TD Cowen Healthcare Conference at 10:30am EST on March 4, 2024.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the 43rd Annual TD Cowen Healthcare Conference at 10:30am EST on March 4, 2024.
  • A live webcast of the presentation will be available on the Events & News – Presentations page of the Company's Investor Relations website.
  • An archived replay of the presentation will be available on the Company's website for 30 days following the live broadcast.

Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Retrieved on: 
Friday, February 23, 2024
Translational medicine, Senior, AAAAI, Mouse, Research, DIA, Animal, Asthma, Anaphylaxis, Eosinophilic bronchitis, Antibody, Allergy, Neutrophil, Therapy, PSA, CD117, CSU, American Academy

The two poster presentations cover separate studies that evaluated briquilimab in Mrgprb2-mediated drug-induced anaphylaxis (DIA) and passive systemic anaphylaxis (PSA).

Key Points: 
  • The two poster presentations cover separate studies that evaluated briquilimab in Mrgprb2-mediated drug-induced anaphylaxis (DIA) and passive systemic anaphylaxis (PSA).
  • Results from both studies demonstrated that a single dose of briquilimab protected against anaphylaxis, as measured by significantly higher core body temperatures in animals treated with briquilimab vs. untreated animals.
  • The oral presentation covers a study that evaluated briquilimab in allergic asthma, which demonstrated that a single dose of briquilimab significantly reduced the numbers of lung mast cells and bronchoalveolar lavage-recovered eosinophils.
  • Additionally, airway-infiltrated eosinophils and neutrophils, as well as airway hyper-responsiveness, decreased in briquilimab-treated mice, suggesting briquilimab has the potential to prevent allergic asthma via mast cell depletion.

Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference

Retrieved on: 
Wednesday, February 7, 2024
CD117, Syndrome, CSU, Therapy, Event, News, Risk, Conference

REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the Oppenheimer 34th Annual Healthcare Conference at 4:40pm EST on February 13, 2024.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that management will present at the Oppenheimer 34th Annual Healthcare Conference at 4:40pm EST on February 13, 2024.
  • The conference is being held in a virtual format.
  • A live webcast of the presentation will be available on the Events & News – Presentations page of the Company's Investor Relations website.
  • An archived replay of the presentation will be available on the Company's website for 30 days following the live broadcast.

Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock

Retrieved on: 
Tuesday, February 6, 2024
Security (finance), CD117, RBC, Telephone, Syndrome, Equity capital markets, Capital market, Public expenditure, Attention, Prospectus, Lexington Avenue, MDS, CSU, Therapy, Risk, RBC Capital Markets, Evercore, Sale, Jasper, Form

Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses.

Key Points: 
  • Each share of common stock will be sold at an offering price of $12.95 per share, for gross proceeds of approximately $50 million, before deducting underwriting discounts and commissions and offering expenses.
  • All of the shares of common stock are being offered by Jasper.
  • The offering is expected to close on or about February 8, 2024, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement and the accompanying prospectus relating to and describing the offering has been filed with the SEC.

Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Retrieved on: 
Monday, February 5, 2024
Poster, Syndrome, AAAAI, CD117, Mouse, Annual general meeting, CSU, Therapy, Risk, Vaccine

REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced two poster presentations and an oral presentation of preclinical briquilimab data at the AAAAI 2024 Annual Meeting, being held February 23-26 in Washington, D.C.
  • Details of the presentations are as follows:
    Abstract Title: Amelioration Of Mrgprb2-Mediated Anaphylactoid Drug Reactions With Briquilimab, An Anti-CD117 Antibody, Through Mast Cell Depletion In Mice Expressing Chimeric Human And Mouse CD117